Addendum to Chapter 10: AIDS-associated lymphoma

Matthew D. Volm and Jamie H. Von Roenn

Due to the addition of new material to Chapter 10, the last two pages of references have been moved to the back of the volume to allow for all updates.


A
ACTG 142 trial, 253–254, 253t
Acute lymphoblastic leukemia, 307–327
   B-cell lineage of, 312
   chemical exposure and, 309
   in children, 307
   classification and characterization of, 309–314
   clinical manifestations of, 315–317, 315t
   cytogenic characterization of, 313–314
   drug resistance in, 314
   epidemiology of, 308
   etiology of, 308–309
   immunophenotyping of, 310–313, 311f
   morphology of, 309, 309f
   prognostic features of, 317–318, 317t
   radiation exposure and, 308–309
   T lymphoblast ontogeny in, 312–313
   treatment of, 318–325 (See also Acute
   lymphoblastic leukemia, treatment of) vs. lymphoblastic lymphoma (LBL), 58
Acute lymphoblastic leukemia, treatment
   of, 318–325
   bone marrow transplantation in, 324–325
   categories of, 319
   consolidation therapy in, 321
   future directions in, 325–327
   maintenance therapy in, 321
   mature B-cell in, 325
   newly diagnosed adult in, 319–323, 320f
   relapsed or refractory disease in, 323–324
   sanctuary sites in, 321–322
   whole-brain radiation therapy in, 322
   See also Hematopoietic growth factors, and leukemia
Acute myeloid leukemia (AML), 281–284
   bone marrow transplantation for, 283
   immunomodulators for, 283–284
   interleukin-2 for, 281–283, 282t
Acute promyelocytic leukemia, current
   approaches to, 125–143
   arsenic compounds in, 141
   ATRA therapy in, clinical trials of, 128–135 (See also All-trans retinoic acid
   (ATRA), clinical trials of)
   ATRA therapy in, complications of, 137–139
   ATRA therapy in, costs of, 139–140
   ATRA therapy in, pharmacology of, 127–128
   ATRA therapy in, role of, 126–127
   diagnostic criteria in, 125–126
   ligand-receptor interactions in, 142
   postremission therapy in, 135–136
   prognostic factors in, 136–137
   retinoids in, other, 140–141
   stem cell transplants in, 141–142
   transcriptional regulation and therapy in, 142–143
Acute promyelocytic leukemia, molecular
   biology of, 75–112
   critical advances in, 111–112
   gene break points in, 77f
   molecular diagnostics in, 108–111 (See also Acute promyelocytic leukemia,
   molecular diagnostics for)
   PML gene in, 76–79 (See also PML gene)
   PML-RARα in [[complete Greek alpha]], 84–91 (See also PML-RARα)
   RARα (alpha receptor for retinoic acid)
   in, 79–84 (See also RARα (alpha receptor for retinoic acid))
   RARα fusion proteins in, alternative, 104–108 (See also RARα fusion
   proteins, alternative)
   retinoic acid resistance in, 97–104 (See also Retinoic acid resistance)
Acute promyelocytic leukemia (Continued)
retinoic response in, 92–97 (See also
Retinoid response)
translocation and fusion genes in, 76t
Acute promyelocytic leukemia, molecular
diagnostic for, 108–111
fresh cell studies in, 102–103
methods overview in, 108
RARα-PML detection in, 110–111
RT-PCR in, for APL diagnosis, 108–109
RT-PCR in, for MRD detection, 109
RT-PCR in, technical improvements in,
109–110
studies in, early, 109
studies in, future, 111
studies in, recent, 110
Adoptive immunotherapy, for diffuse
aggressive lymphoma, 64
AIDS-associated lymphoma, 241–260
conclusions in, 259–260
epidemiology of, 241–243
extranodal sites in, 250, 250t
histology of, 243
pathogenesis of, 244–250 (See also AIDS-
associated lymphoma, pathogenesis of)
presentation of, 250–251
primary CNS lymphoma in, 257–259
prognostic factors for, 251
staging of, 250–251
treatment of, 251–257 (See also AIDS-
associated lymphoma, treatment of)
AIDS-associated lymphoma, pathogenesis
of, 244–250
B-cell stimulation in, 247–248
cytokines in, endogenous, 248–249
EBV in, 245–246
Kaposi's sarcoma herpes virus (KSHV)
in, 246–247
molecular genetics in, 249–250
posttransplant lymphomas vs. HIV-
associated lymphomas in, 244t
posttransplant lymphoproliferative
disorders paradigm in, 244–245
T-cell function loss in, 247–248
AIDS-associated lymphoma, treatment of,
251–257
ACTG 142 trial in, 253–254, 253t
antiretroviral therapy in, 255–256
chemotherapy in, 255–256
CNS disease in, secondary, 255
colony stimulating factors in, 254–255
dose intensity in, 252–254
m-BACOD regimen in, low dose, 252,
252t
myelosuppression in, 254–255
new approaches in, 256–257
refractory or relapsed conditions in,
second-line therapy for, 256
Allogeneic transplants, 181–184
for ALL vs. AML, 324
alternate donors for, 183
clinical trial results for, 182, 182t
graft-versus-myeloma effect in, 184
in myelodysplasia, 346, 352
prognostic features for, 183
vs. autologous transplants, 181, 184–186
All-trans retinoic acid (ATRA)
in APL gene translocations, 76t
for chronic myeloid leukemia (CML),
279
for myelodysplasia, 339t, 342
in PML-RARα in vitro studies, 89
in PML-RARα isoforms, 85–86
and pregnancy, 137–138
in retinoic response, 92–97
All-trans retinoic acid (ATRA), clinical
trials of, 128–135
Argentinean series on, 134
British MRC ATRA Trial on, 134
EORTC on, 133–134
European APL 91 study on, 130–132
GIMEMA on, 133–134
Japan Adult Leukemia Study Group
(JALSG) on, 129–130
M.D. Anderson Cancer Center on, 133
New York trial on, 129
North American Intergroup 0129 study
on, 132
remission rates in, 129, 134–135
in vitro study results and, 128
Alpha interferon
for B-cell malignancies, 286–288, 287t
for myeloid leukemias, 275
Alpha receptor for retinoic acid (RARα).
See RARα
Am580, 140
Anaplastic large cell lymphoma (ALCL)
in non-Hodgkin's lymphoma
classification, 16–18, 17r
therapy for, 60–61
Anaplastic lymphoma kinase (ALK), 17–18,
60
Androgens, 353
Anthracycline
in adult ALL, 319
in ATRA therapy, 135
Antimicrobial function enhancement, in
leukemia, 207–210
cytokines in, 207–208, 208t
fungal infection mortality in, 209–210, 209t
GM-CSF in, 208–210
Antiretroviral therapy
in AIDS-associated lymphoma, 255–256
for B-cell non-Hodgkin’s lymphoma (NHL), 242
Apoptosis
in myelodysplasia, 335–336
in S phase cell recruitment, 211–212
Arsenic compounds, for acute promyelocytic leukemia, 141
Aspergillus fumigatus, in AML, 207, 209t
ATRA. See all-trans retinoic acid (ATRA)
Australian Leukemia Study Group, 138–139
Austrian Cooperative Group, 287–288, 287t
Autocrine/paracrine loop interruption, 216–218
Autologous transplants
for multiple myeloma, 172–180
vs. allogeneic transplants, 184–186
Azacytidine, 343
AZT, 242

B
B-cell
Epstein-Barr virus on, 28–29, 28f
myeloma, 286–289 (See also B-cell malignancies, novel approaches to) stimulation of, in AIDS-associated lymphoma, 247–248
B-cell lymphoma
in anaplastic large cell lymphoma classification, 17
from MALT lymphoma, 13
as marginal zone lymphoma, 12
in node-based marginal zone lymphoma, 14
ontogeny schematic of, 311f
in REAL classification, 7–8, 8t
vs. T-cell, 4, 6
B-cell malignancies, novel approaches to, 286–289
alpha interferon in, 286–288, 287t
cyclosporine A (CSA) in, 288–289
erthropoietin in, 288
interleukin-2 in, 288
interleukin-4 in, 292
myeloma in, 286–288
B-cell malignancies, resistance to, 267–272
future directions in, 271–272
human studies in, 270–272
preclinical experimental models in, 267–270
B-cell non-Hodgkin’s lymphoma (NHL), 241
antiretroviral drugs on, 242
Working Formulation categories for, 243, 243t
Bcl-1 gene, 11
Bcl-2 gene
in autocrine/paracrine loops, 216
in B-cell malignancies, 270–271
in primary CNS lymphoma, 258
in retinoic acid resistance, 104
in retinoid response, 94
Bcl-6 gene, in HIV-associated lymphomas, 249–250
Benzene, 309
Bestatin (Ubenimex), 283–284
B2-microglobulin in [[comp-l.c. Greek beta]], in multiple myeloma, 161, 176
Bone marrow transplantation
for acute myeloid leukemia (AML), 283
for anaplastic large cell lymphoma (ALCL), 61
for diffuse aggressive lymphoma, initial treatment of, 52–53, 53t
for diffuse aggressive lymphoma, relapsed, 56
interleukin-2 in, 291–292
for multiple myeloma (See Multiple myeloma, transplantation for)
Breakpoint regions, in PML-RARα, 84–85
British MRC ATRA Trial, 134
Burkitt’s lymphoma
C-myc rearrangements in, 249
Epstein-Barr virus in, 35–36, 245–246
therapy for, 57–58
Busulfan (BU), 276–277, 277t

C
Canadian Cooperative Group, 287–288, 287t
Cancer and Leukemia Group B study on chronic myeloid leukemia, 276
on leukemia neutropenia, 205
Candida albicans, in AML, 207, 209t
CD4 cells
in B-cell malignancies, 270
in HIV-associated lymphomas, 242
CD5 cells
in mantle cell lymphoma, 11
monoclonal antibodies and, 231
CD8 cells, in EBV infection, 31
CD30, 17, 60
Cell differentiation, induction of, 214
Cellular expression, of acute promyelocytic leukemia, 78–79
Central nervous system (CNS) disease
  in acute lymphoblastic lymphoma, 316
  in AIDS-associated lymphoma, 255, 257–259
  primary, 242
Centroblast, 3
Centrocyte, 3
Chemotherapy
  for AIDS-associated lymphoma, 255–256
  for anaplastic large cell lymphoma
    (ALCL), 16
  for B-cell malignancies, 270
  for chronic myeloid leukemia, 276–277, 277t
  for diffuse aggressive lymphomas, 50–53
  for diffuse aggressive lymphomas,
    conventional-dose salvage, 55–56
  for myelodysplasia, 286, 346, 348t–351t
  for non-Hodgkin’s lymphoma, 289–291, 290t
  for primary adult ALL, 319–323
  for primary CNS lymphoma, 259
2-Chlorodeoxyadenosine (2-CDA), 230
CHOP regimen, 50
  for anaplastic large cell lymphoma in
    (ALCL), 60–61
  new approaches and, 51–54
  vs. VMT, 57
Chromosome, translocation of
  in acute lymphoblastic leukemia, 313–314
  in acute promyelocytic leukemia, 76t
  in anaplastic large cell lymphoma, 17–18, 60
  in Burkitt’s lymphoma, 35, 57–58, 313–314
  in HIV-associated lymphomas, 249
  in MALT lymphoma, 13
  in mantle cell lymphoma, 11
  11Q13 in, 159–160
Chromosome 13, 159
Chronic Granulomatous Disease Study Group, 209
Chronic lymphocytic leukemia (CLL), 11
Chronic myeloid leukemia (CML), 276–281
  accelerated CML in, 278
  all-trans retinoic acid (ATRA) for, 279
  donor leukocyte infusions for, 280
  future directions in, 280–281
  gamma interferon for, 279
  interferon therapy for, 276–278, 277t
  juvenile CML in, 280
  low-dose cytarabine for, 278–279
C-myc gene, 20
  in HIV-associated lymphomas, 245, 249
  in multiple myeloma, 160
Colonization, follicular, 12
Colony stimulating factors. See also
  Granulocyte-macrophage colony
  stimulating factor (GM-CSF)
  in AIDS-associated lymphoma, 254–255
Combination approaches, for cutaneous T-cell lymphoma, 236–237
Consolidation therapy, 321
COPA regimen, 290–291
C-reactive protein, in multiple myeloma,
  162–163
Cutaneous T-cell lymphoma, 227–237
  combination approaches for, 236–237
  fusion toxin therapies for, 233–234
  interleukin-2 for, 228
  monoclonal antibodies for, 231–233
  purine analogue therapy for, 229–231
  retinoids for, 227–228
  thymopentin for, 234–235
Cyclin D1 protein, 11
Cyclophosphamide, 319–320
Cyclosporine
  for B-cell malignancies, 288–289
  for cytopenias, 294
  for lymphoproliferative disease, 32
  for myelodysplasia, 354
Cytarabine
  for adult ALL, 321
  in ATRA therapy, 130, 135
  for chronic myeloid leukemia (CML),
    278–279
  for relapsed ALL, 323
Cytogenetic abnormalities, in multiple myeloma, 158–160
Cytokines
  activity factors for, in multiple myeloma,
    161–164
  in AIDS-associated lymphoma, 248–249
  for AML neutropenia, 199–200, 200t
  in AML priming therapy, 212, 213t
  antileukemic effects of, 214–216
  in B-cell malignancies, 268, 269t
  in PML cellular expression, 78
Cytopenia, cyclosporine for, 294
D
DAB$_{44}$IL-2, 233–234
DAB$_{44}$IL-2, 233
Danazol, 353–354
Daunorubicin, in ATRA therapy, 130
Dendritic cells, 292
Deoxycoformycin (DCF), 229
Desferrioxamine, subcutaneous, 354
Dexamethasone
for AIDS-associated lymphoma, 258
in ATRA therapy, 138–139
DHAP regimen, 54, 56
Differentiation therapy, 338–343, 339t–341t
Diffuse aggressive lymphoma, therapy for, 47–64
adoptive immunotherapy in, 64
anaplastic large cell lymphoma in (ALCL), 60–61
biology of, 48
Burkitt's and Burkitt's like lymphoma in, 57–58
cellular markers in, 50
chemotherapy in, conventional-dose salvage, 55–56
chemotherapy in, high dose, 56
chemotherapy in, with stem cell support, 52–53
classification of, 47–48, 48t
dose intensity in, 51–52
dose intensity in, without stem cell support, 52
elderly in, 56–57
high-dose sequential chemotherapy (HDSC) in, 54
high-risk disease patient determination in, 49–50
historical perspective to treatment in, 50–51
immunotherapy for, 62–64
immunotoxins in, 63
initial treatments in, 51–54
lymphoblastic lymphoma in, 58–60
monoclonal antibodies in, 62–63
peripheral T-cell lymphomas (PTCL) in, 61–62
prognostic factors for, 48, 49t
radioimmunotherapy in, 63
relapsed aggressive lymphoma treatments in, 55–56
retinoic acid in, 62
small noncleaved cell lymphoma in, 57–58
vaccine therapy in, 63–64
Dimerization, in PML-RARα interactions, 86–88
DNA
hypomethylation of, 343
in multiple myeloma, 158–160
DNA binding
in PML-RARα, 88–89
in RARα (alpha receptor for retinoic acid), 79
Donor leukocyte infusions, 280
Dose intensity
in AIDS-associated lymphoma, 252–254
in diffuse aggressive lymphoma, 51–52

E
Eastern Cooperative Oncology Group (ECOG)
on AML induction therapy, 209–210
on CHOP protocol, 51
on neutropenia, 202–204
on non-Hodgkin's lymphoma, 289–290, 290t
EORTC
on ATRA, 133–134
on non-Hodgkin's lymphoma, 290t, 291
Episomes, 31–32
in Burkitt's lymphoma, 36
Epstein-Barr virus, 27–38
in Burkitt's lymphoma, 35–36
characterization of, 31–32
detection of, 32
gene expression in, 29
in HIV-associated lymphoma, 37–38, 245–246
in Hodgkin's disease, 36–37
immune response to, 31
latent infection of, 28–30
and lymphoma, 27–38
lytic infection of, 30–31
in nasal lymphoma, 38
neoplastic diseases and latency of, 29
in NK-cell lymphoma, 38
in posttransplantation lymphoproliferative disorders (PT-LPD), 18–19, 32–35
serologic studies of, 27–28
in T-cell lymphoma, 38
vs. human herpes virus, 27
E-region, in RARα, 81–83
Erythropoietin
for B-cell malignancies, 288
for myelodysplasia, 285, 342, 352–353
Etretinate, 227
European APL 91 study, 130–132
European Study Group, on erythropoietin, 288
Fluorescent in situ hybridization (FISH), 159
Follicular center cells, 3
Follicular colonization, 12
Follicular lymphoma, 2–3
French Lymphoma Trials Group (GELA), 52–53
French Myeloma Intergroup trial, 177
French-American-British (FAB) group, 335–337
Fungal infection, 207–210
Fusion toxin therapy, for cutaneous T-cell lymphoma, 233–234
Fusion variants, in PML-RARα, 86–88

G
Gallium-67 citrate imaging, 49–50
Gamma interferon, for chronic myeloid leukemia (CML), 279
GELA study
on diffuse aggressive lymphoma, 52–53
on non-Hodgkin’s lymphoma, 290, 290t
Gene expression, in Epstein-Barr virus, 29
Gene structure, of acute promyelocytic leukemia, 76–78
Gene translocations. See Chromosome, translocation of
German CML Study Group, 277
German Myeloma Treatment Group, 288
Giant cells, in anaplastic large cell lymphoma (ALCL), 16
GIMEMA, 133–134
Graft-versus-host disease (GVHD)
in acute myeloid leukemia, 283
in bone-marrow transplant, 347
in multiple myeloma transplantation, 184
Graft-versus-leukemic effect (GVL), 324–325
Granulocyte-macrophage colony stimulating factor (GM-CSF)
antimicrobial function of, 207–210
in autocrine/paracrine loops, 216–218
for B-cell malignancies, 268–270
for leukemia neutropenia, 201–202, 201t
in leukemic cell proliferation, 196
for myelodysplasia, 285, 336, 352
in S phase cycle cell recruitment, 210–212
Hematologic malignancies, novel approaches to, 275–296
acute myeloid leukemia (AML) in, 281–284 (See also Acute myeloid leukemia (AML))
alpha interferon in, 275
B-cell malignancies in, 286–289 (See also B-cell malignancies, novel approaches to)
chronic myeloid leukemia (CML) in, 276–281 (See also Chronic myeloid leukemia (CML))
future directions in, 294–295
myelodysplasia in, 284–286 (See also Myelodysplasia)
non-Hodgkin’s lymphoma in, 289–294
(See also Non-Hodgkin’s lymphoma, novel approaches to)
Hematopoietic growth factors, and leukemia, 195–219
antimicrobial function enhancement in,
207–210 (See also Antimicrobial function enhancement, in leukemia)
autocrine/paracrine loop interruption in, 216–218
cell differentiation induction in, 214
cytokines in, 214–216
leukemic cell proliferation in, 196–199
(See also Leukemic cell proliferation, growth factors on)
neutropenia reduction in, 199–207 (See also Neutropenia, in leukemia)
S phase cell recruitment in, 210–214 (See also S phase cell recruitment)
stem cell protection in, 218–219
Hematopoietic growth factors, in
myelodysplasia, 352–353
Hematopoietic stem cells, in multiple myeloma, 180–181
The Hemophilia Malignancy Study Group, 241–242
Herpes virus vs. Epstein-Barr virus, 27
Heterodimerization, in PML-RARα interactions, 87–88
Hexamethylene bisacetamide, 342
High-dose sequential chemotherapy (HDSC), 54
Histiocytic lymphoma, 2
Histone acetylation, 81–83, 82f
HIV-associated lymphoma. See also AIDS-associated lymphoma
Epstein-Barr virus in, 37–38, 245–246
HL-60 cells, in retinoic acid resistance, 99–100

HAMA (human antimouse antibodies), 231–232
Helicobacter pylori, in mucosa-associated lymphoid tissue (MALT), 12–13

Gallium-67 citrate imaging, 49–50
Gamma interferon, for chronic myeloid leukemia (CML), 279
GELA study
on diffuse aggressive lymphoma, 52–53
on non-Hodgkin’s lymphoma, 290, 290t
Gene expression, in Epstein-Barr virus, 29
Gene structure, of acute promyelocytic leukemia, 76–78
Gene translocations. See Chromosome, translocation of
German CML Study Group, 277
German Myeloma Treatment Group, 288
Giant cells, in anaplastic large cell lymphoma (ALCL), 16
GIMEMA, 133–134
Graft-versus-host disease (GVHD)
in acute myeloid leukemia, 283
in bone-marrow transplant, 347
in multiple myeloma transplantation, 184
Graft-versus-leukemic effect (GVL), 324–325
Granulocyte-macrophage colony stimulating factor (GM-CSF)
antimicrobial function of, 207–210
in autocrine/paracrine loops, 216–218
for B-cell malignancies, 268–270
for leukemia neutropenia, 201–202, 201t
in leukemic cell proliferation, 196
for myelodysplasia, 285, 336, 352
in S phase cycle cell recruitment, 210–212

H
HAMA (human antimouse antibodies), 231–232
Helicobacter pylori, in mucosa-associated lymphoid tissue (MALT), 12–13

Hematologic malignancies, novel approaches to, 275–296
acute myeloid leukemia (AML) in, 281–284 (See also Acute myeloid leukemia (AML))
alpha interferon in, 275
B-cell malignancies in, 286–289 (See also B-cell malignancies, novel approaches to)
chronic myeloid leukemia (CML) in, 276–281 (See also Chronic myeloid leukemia (CML))
future directions in, 294–295
myelodysplasia in, 284–286 (See also Myelodysplasia)
non-Hodgkin’s lymphoma in, 289–294
(See also Non-Hodgkin’s lymphoma, novel approaches to)
Hematopoietic growth factors, and leukemia, 195–219
antimicrobial function enhancement in,
207–210 (See also Antimicrobial function enhancement, in leukemia)
autocrine/paracrine loop interruption in, 216–218
cell differentiation induction in, 214
cytokines in, 214–216
leukemic cell proliferation in, 196–199
(See also Leukemic cell proliferation, growth factors on)
neutropenia reduction in, 199–207 (See also Neutropenia, in leukemia)
S phase cell recruitment in, 210–214 (See also S phase cell recruitment)
stem cell protection in, 218–219
Hematopoietic growth factors, in
myelodysplasia, 352–353
Hematopoietic stem cells, in multiple myeloma, 180–181
The Hemophilia Malignancy Study Group, 241–242
Herpes virus vs. Epstein-Barr virus, 27
Heterodimerization, in PML-RARα interactions, 87–88
Hexamethylene bisacetamide, 342
High-dose sequential chemotherapy (HDSC), 54
Histiocytic lymphoma, 2
Histone acetylation, 81–83, 82f
HIV-associated lymphoma. See also AIDS-associated lymphoma
Epstein-Barr virus in, 37–38, 245–246
HL-60 cells, in retinoic acid resistance, 99–100

370

370
Hodgkin's disease, Epstein-Barr virus in, 36-37
Human antimouse antibodies (HAMA), 231-232
Human response elements (HREs), in RARα (alpha receptor for retinoic acid), 79-81
Hydroxyurea (HU), 276-277, 277t

I
Idarubicin, 133
Idiotype, 267
Id-KLH immunization, 268-270, 269t
Immortalization, of Epstein-Barr virus, 29
Immunee response
to Epstein-Barr virus, 31
T-cells and, 267-272
Immunodeficiency disorders
latency gene expression in, 29
lymphoproliferative disorders as, 18
Immunofluorescence assays, 31
Immunoglobulin receptors, in B-cell malignancies, 267-272
Immunomodulation
for acute myeloid leukemia (AML), 283-284
posttransplant, in multiple myeloma, 186-187
Immunophenotype, in non-Hodgkin's lymphoma classification, 9
Immunotherapy, for diffuse aggressive lymphoma, 62-64
adoptive immunotherapy in, 64
immunotoxins in, 63
monoclonal antibodies in, 62-63
radioimmunotherapy in, 63
vaccine therapy in, 63-64
Immunotoxins, for diffuse aggressive lymphoma, 63
Infection, non-clonal vs. clonal, 30f
Interferon
for chronic myeloid leukemia (CML), 276-278, 277t
for myelodysplasia, 342
Interleukin
for acute myeloid leukemia (AML), 281-283, 282t
in autocrine growth mechanism, 216-218
for B-cell malignancies, 270, 288, 292
for bone marrow transplants, 291-292
for cutaneous T-cell lymphoma, 228
for multiple myeloma, 162-163
for myelodysplasia, 353
for non-Hodgkin's lymphoma, 291-292
Intermediately differentiated lymphocytic lymphoma (IDL), 10
International Lymphoma Study Group (ILSG), 7
International Non-Hodgkin's Lymphoma Risk Factor Project, 251
International Prognostic Index, 9
in diffuse aggressive lymphomas, 49t
International Prognostic Scoring System (IPSS), 336-337
Iodine-labeled M195, 284
Isoform differentiation, in PML-RARα, 85-86
Isotretinoin, for cutaneous T-cell lymphoma, 227
Italian Cooperative Study Group, 276-277

J
Japan Adult Leukemia Study Group (JALSG), 129-130

K
Kaposi's sarcoma herpes virus (KSHV), 246-247
Kiel classification
in non-Hodgkin's lymphoma, 2-4
updated, in non-Hodgkin's lymphoma, 6-7, 6t
Kouseisho Leukemia Study Group, 277-278

L
Lactate dehydrogenase, in acute lymphoblastic leukemia, 316
L-asparaginase, 319-320
Latent infection, of Epstein-Barr virus, 28-30
Leukemia
acute lymphoblastic, 307-327 (See also Acute lymphoblastic leukemia)
acute myelogenous, 195-219 (See also Hematopoietic growth factors, and leukemia)
acute myeloid, 281-284 (See also Acute myeloid leukemia)
acute promyelocytic (See Acute promyelocytic leukemia, current approaches to; Acute promyelocytic leukemia, molecular biology of; Acute promyelocytic leukemia, molecular diagnostics for)
all-trans retinoic acid (ATRA) for, 129-130, 279
alpha interferon for, 275

371
Leukemia (Continued)
antimicrobial function enhancement in, 207–210
arsenic compounds for, 141
Australian Leukemia Study Group on, 138–139
bone marrow transplantation for, 283
Cancer and Leukemia Group B study on, 205, 276
cellular expression of, 78–79
chemotherapy for, 276–277, 277t
chromosome translocation in, 76t, 313–314
chronic lymphocytic, 11
chronic myeloid, 276–281 (See also
Chronic myeloid leukemia)
cytarabine for, 278–279
gamma interferon for, 279
gene structure of, 76–78
graft-versus-host disease (GVHD) in, 283
granulocyte-macrophage colony
stimulating factor (GM-CSF) for, 201–202, 201t
hairy cell, 229, 289
interferon for, 276–278, 277t
interleukin for, 281–283, 282t
Japan Adult Leukemia Study Group (JALSG) on, 129–130
Kouseisho Leukemia Study Group on, 277–278
lactate dehydrogenase in, 316
magnetic field exposure on, 309
M.D. Anderson Cancer Center on, 276
monoclonal antibodies for, 284
neutropenia in, 199–207 (See also
Neutropenia, in leukemia)
postremission therapy for, 135–136
prognostic factors for, 136–137
retinoic acid resistance in, 98–99
retinoic acid syndrome (RAS) in, 138
RT-PCR in, 108–110
stem cell transplants for, 141–142
thrombocytopenia in, 315–316
Leukemic cell proliferation, growth factors on, 196–199
AML blast receptors in, 196–197, 197t
GM-CSF in, 196
multiple growth factors in, 198
thrombopoietin (TPO) in, 197
tumor necrosis factor (TNF) in, 197–198
Ligand binding domain (LBD), in RARα
(alpha receptor for retinoic acid), 79
Low dose m-BACOD regimen, 252, 252t
Low-grade lymphoma of mucosa-associated lymphoid tissue (MALT), in non-
Hodgkin’s lymphoma classification, 12–13, 13f
Lukes-Collins classification, in non-
Hodgkin’s lymphoma classification, 2–4, 3t
Lymphoblastic lymphoma, therapy for, 58–60
cell structure in, 58
remission factors in, 59–60
survival rate in, 58–59
Lymphocytes, in Epstein-Barr viral
infection, 29
Lymphoid cells, 3
Epstein-Barr lytic infection of, 30–31
Lymphokine-activated killer (LAK) cells, 281
Lymphoma. See also specific types
AIDS-associated, 241–260 (See also
AIDS-associated lymphoma)
B-cell (See B-cell lymphoma)
cutaneous T-cell, 227–237 (See also
Cutaneous T-cell lymphoma)
diffuse aggressive, 47–64 (See also Diffuse
aggressive lymphoma)
histiocytic, 2
non-Hodgkin’s, 1–20 (See also Non-
Hodgkin’s lymphoma, classification of)
Lytic infection, of Epstein-Barr virus, 30–31

M
M195, 284
Magnetic field exposure, and leukemia, 309
Malignancies
B-cell, CD4 cells in, 270
B-cell, cytokines in, 268, 269t
hematologic, novel approaches to, 275–296 (See also Hematologic
malignancies, novel approaches to)
The Hemophilia Malignancy Study
Group on, 241–242
Mantle cell lymphoma, in non-Hodgkin’s
lymphoma classification, 9–11, 10f
Marginal zone lymphoma, in non-Hodgkin’s
lymphoma classification, 11–12
Mayo Clinic, on erythropoietin, 288
m-BACOD regimen, 252, 252t
M.D. Anderson Cancer Center, 133
on chronic myeloid leukemia, 276
Memorial Sloan Kettering Group, 284
Methotrexate, 314
Microspeckles, 86

372
Mineral-oil-induced plasmacytomas (MOPCs), 267–268

Monoclonal antibodies
for acute myeloid leukemia, 284
for cutaneous T-cell lymphoma, 231–233
for diffuse aggressive lymphoma, 62–63
for non-Hodgkin’s lymphoma, 293

Monocytoid B cells, 11

Monocytoid B-cell lymphoma, in non-Hodgkin’s lymphoma classification, 14, 14f

Mononucleosis, in Hodgkin’s disease, 36

MRD, detection of, 109

Mucosa-associated lymphoid tissue (MALT), in non-Hodgkin’s lymphoma classification, 12–13, 13f

Multicenter AIDS Cohort Study (MACS), 242

Multiple myeloma, prognosis in, 155–166 [ß2-microglobulin in [comp-lc. Greek beta]], 161
C-reactive protein in, 162–163
cytogenetic abnormalities in, 158–160
cytokine activity factors in, 161–164
DNA content in, 158–160
future directions for, 165–166
host factors in, 164–165
IL-6 in, 162
IL-6 receptor in, soluble, 163
immunohistochemistry in, 161
oncogenes in, 160
phenotyping in, 161
plasma cell labeling index (PCLI) in, 155–157, 157t
plasma cell morphology in, 160–161
plasma cells in, circulating, 164
proliferation assays in, other, 157–158
regulatory cells in, 164
serum markers in, 163–164
tumor burden indicators in, 161–164
tumor suppressor genes in, 160

Multiple myeloma, transplantation for, 171–186
allogeneic transplants in, 181–184 (See also Allogeneic transplants)
autologous transplants in, 172–180
clinical endpoints in, 173–175, 174f, 175t
French Myeloma Intergroup trial on, 177
future perspectives in, 187–188
hematopoietic stem cells in, 180–181
high risk patients in, 178–179
late myeloma in, 175, 176t
newly diagnosed patients in, 176–177
phase II studies of, 172t
posttransplant immunomodulation in, 186–187
posttransplant myelodysplasia risk in, 179–180
posttransplant relapse in, 179
standard dose resistance and, 171
stem cell selection in, 181
tandem autotransplants in, 172–173, 176
Total Therapy trial in, 177
transplantation timing in, 178
tumor purging in, 181

Mycosis fungoides (MF), 227

Myelodysplasia, 284–286
chemotherapy for, 286
derifferentiating agent evaluation in, 285–286
erythropoietin for, 285
hematopoiesis in, 284
neutropenia in, 285

Myelodysplasia, therapy advances in, 335–355
allogeneic bone marrow transplantation in, 346, 352
apoptosis in, 335–336
conceptual categorization in, 337–338, 338f
hematopoietic growth factors in, 352–353
intensive chemotherapy for, 346, 348t–351t
international scoring system for, 336–337
low-dose chemotherapy in, 343–346, 344t–345t
noncytotoxic ‘differentiation’ therapy in, 338–343, 339t–341t
summary approach algorithm in, 354, 355f
therapies for, miscellaneous, 353–354
Myeloid leukemia cell lines, in retinoic acid resistance, 98–99

Myeloma
agents for, 286–288
multiple (See Multiple myeloma)

Myelosuppression, in AIDS-associated lymphoma, 254–255

N
Nasal lymphoma, Epstein-Barr virus in, 38
National Cancer Institute
on HIV-seropositive hemophiliacs, 241–242
on purine nucleoside therapies, 229–230, 230t
on thymopentin, 235
NB4 cells
in ATRA mechanism, 142

373
NB4 cells (Continued)
in retinoic acid resistance, 100-102
in retinoid response, 93
Neurotoxicity, of purine analogues, 230
Neutropenia, in leukemia, 199-207
   Cancer and Leukemia Group B study in, 205
cytokines for AML in, 199-200, 200t
disease-free survival rates in, 204f
Eastern Cooperative Oncology Group trial on, 202-204
GM-CSF in, recombinant, 201-202, 201t
in myelodysplasia, 285
overall survival rates in, 203f
study design endpoints in, 201
trial data summary in, 205-207, 206t
New York trial, for ATRA, 129
NK-cell
   lymphoma, Epstein-Barr virus in, 38
   neoplasms of, 8t
Node-based marginal zone lymphoma, in
   non-Hodgkin’s lymphoma classification, 14, 14f
Noncytotoxic/differentiation therapy, 338-343, 339t-341t
Non-Hodgkin’s lymphoma, classification of, 1-20
   anaplastic large cell lymphoma (ALCL) in, 16-18, 17f
   future classification in, 20
   Kiel classification in, 2-4
   Kiel classification in, updated, 6-7, 6t
   low-grade lymphoma of mucosa-associated lymphoid tissue (MALT) in, 12-13, 13f
   Lukes-Collins classification in, 2-4, 3t
   mantle cell lymphoma in, 9-11, 10f
   marginal zone lymphoma in, 11-12
   monocytoid B-cell lymphoma in, 14, 14f
   node-based marginal zone lymphoma in, 14, 14f
   posttransplantation lymphoproliferative disorders (PT-LPD) in, 18-20
   Rappaport classification in, 1-2, 2t
   Revised European-American Lymphoma (REAL) classification in, 7-9, 8t
   splenic marginal zone lymphoma in, 14-16, 15f
   WHO classification in, 9
   Working Formulation in, 4-5, 5t
Non-Hodgkin’s lymphoma, novel approaches to, 289-294
   alpha interferon for, 289-291
   COPA regimen for, 290-291
interleukin-2 for, 291-292
interleukin-4 for, 292
   monoclonal antibodies in, 293
   vaccines for, 293-294
Nordic Cooperative Group, 287-288, 287t
Nordic Myeloma Study Group, 286
North American Intergroup 0129 study, 132
NPM-RARα, 107
Nuclear bodies (NB), in PML cellular expression, 78-79
Nucleophosmin (NPM), 17-18, 60
NuMA-RARα, 107-108
O
   Oncogenes, in multiple myeloma, 160
   Organ transplants, Epstein-Barr virus in, 32, 34
P
   Papilloma viruses, 31
   Paracrine loops, 216-218
   PARMA trial, 56
   PBSC, 53-54
   Peripheral T-cell lymphomas (PTCL), therapy for, 61-62
   P-glycoprotein
      in drug resistance, 314
      in retinoic acid resistance, 103-104
   Phenotyping, in multiple myeloma, 161
   Philadelphia chromosome, 313-314, 318
   Plasma cell labeling index (PCLI), for multiple myeloma, 155-157, 157t
   Plasma cells, in multiple myeloma circulating, 164
   morphology of, 160-161
   Plasmacytomas, mineral-oil-induced, 267-268
   PLZF, 105
   PLZF-RARα/RARα-PLZF function of, 106-107
          structure of, 105-106
   PML gene
      cellular expression in, 78-79
      functional activity in, 79
      gene structure in, 76-78
   PML-RARα
      ATRA-regulated gene expression in, 94-95
      breakpoint regions in, 84-85
      DNA binding in, 88-89
      fusion variants in, 86-88
      isoform differentiation in, 85-86
      in leukemogenesis, 142
      overexpression of, 93-94
subcellular localization of, 86
transcriptional activity in, 88–89
in vitro functional studies for, 89
in vivo functional studies for, 89–91
*Pneumocystis carinii*, 229–230
prophylactic regimens for, 242
Polymerase chain reaction (PCR)
for Epstein-Barr virus detection, 32 (See also Reverse transcription-polymerase chain reaction (RT-PCR))
for immortalized B-cells, 29
Polymorphic B-cell hyperplasia, 18–19
Postremission therapy, for acute promyelocytic leukemia, 135–136
Posttransplant immunomodulation, in multiple myeloma, 186–187
Posttransplant lymphomas, vs. HIV-associated lymphomas, 244t
Posttransplant myelodysplasia risk, in multiple myeloma, 179–180
Posttransplant relapse, in multiple myeloma, 179
Posttransplantation lymphoproliferative disorders (PT-LPD)
Epstein-Barr virus in, 32–35
in non-Hodgkin’s lymphoma classification, 18–20
Primary CNS lymphoma, 242
in AIDS-associated lymphoma, 257–259
Prognostic factors, for acute promyelocytic leukemia, 136–137
Proliferation assays, for multiple myeloma, 157–158
Proline, 77
ProMACe, 270
Promyelocytic leukemia. See Acute promyelocytic leukemia
Psoralen, 236
Purine analogue therapy, for cutaneous T-cell lymphoma, 229–231
Purine nucleotide phosphorylase, 231
PUVA, 228, 237

**R**
Radiation exposure, on leukemia, 308–309
Radioimmunotherapy, for diffuse aggressive lymphoma, 63
Radiotherapy
for initial treatment of diffuse aggressive lymphomas, 50–51
for relapsed diffuse aggressive lymphomas, 56
Rappaport classification, in non-Hodgkin’s lymphoma classification, 1–2, 2t
RARα (alpha receptor for retinoic acid), 75, 79–84
E-region/ligand binding domain (LBD) in, 81–83
expression heterogeneity in, 83–84
gene promoter model for, 82f
and nuclear receptor gene superfamily, 79–81
retinoid X receptors (RXRs) in, 80, 82f structure of, 80f
RARα fusion proteins, alternative, 104–108
NPM-RARα in, 107
NuMA-RARα in, 107–108
overview of, 104
PLZF as, 105
PLZF-RARα/RARα-PLZF function in, 106–107
PLZF-RARα/RARα-PLZF structure in, 105–106
RARα-PML, detection of, 110–111
RARc (retinoic acid response elements)
in heterogeneity of RAR expression, 84
in HRE specificity, 80
in PML-RARα isoforms, 85–86
Reed-Sternberg cells, 245
Refractory Anemia with Excess Blasts (RAEB), 338, 352
Refractory conditions
in acute lymphoblastic leukemia, 323–324
in AIDS-associated lymphoma, 256
Resistance, to B-cell malignancies, 267–272.
See also B-cell malignancies, resistance to
Retinoblastoma, on AML blasts, 218
Retinoic acid
alpha receptor for, 75, 79–84 (See also RARα)
for diffuse aggressive lymphoma, 62
response element for (See RARE (retinoic acid response elements))
Retinoic acid resistance, 97–104
bcl-2 gene in, 104
fresh APL cell studies in, 102–103
HL-60 cells in, 99–100
in myeloid leukemia cell lines, 98–99
NB4 cells in, 100–102
P-glycoprotein in, 103–104
pharmacologic vs. cellular basis of, 97–98
Retinoic acid syndrome (RAS)
in acute promyelocytic leukemia, 138
in myelodysplasia, 342
Retinoid response, 92–97
ATRA modulated genes in, 96
Retinoid response (Continued)
ATRA-regulated PML-RAR\(\alpha\) gene expression in, 94–95
bel-2 role in, 94
nuclear reorganization in, 96–97
PML-RAR\(\alpha\) overexpression in, 93–94
RXR-mediated gene expression in, 95–96
success of ATRA treatment and, 92–93
in vitro NB4 cell line studies in, 93
Retinoid X receptors (RXRs), 80, 82f
on retinoid response gene expression, 95–96
Retinoids
for cutaneous T-cell lymphoma, 227–228
toxicity profile of, 228
Reverse transcription-polymerase chain reaction (RT-PCR), for acute promyelocytic leukemia, 108–110
Revised European-American Lymphoma (REAL) classification, in non-Hodgkin’s lymphoma classification, 7–9, 8t
RING motif, 77

S
S phase cell recruitment, 210–214
apoptosis in, 211–212
cytokines as priming agents in, 212, 213t
in vivo priming in, 210–211
Sanctuary sites, 321–322
Second-line therapy, for AIDS-associated lymphoma, 256
Serology, of Epstein-Barr virus, 27–28
Serum markers, for multiple myeloma, 163–164
Sezary syndrome, 227
Small noncleaved cell lymphoma (SNCL), therapy for, 57–58
Splenic marginal zone lymphoma, in non-Hodgkin’s lymphoma classification, 14–16, 15f
Stem cell
for diffuse aggressive lymphoma, 52–53, 53f
protection of, 218–219
Stem cell transplants
for acute promyelocytic leukemia, 141–142
for multiple myeloma (See Multiple myeloma, transplantation for)
Subcellular localization, of PML-RAR\(\alpha\), 86
Survival rates

for diffuse aggressive lymphomas, 49f
for diffuse aggressive lymphomas, bone marrow transplantation in, 56
in lymphoblastic lymphoma, 58–59

T
T-101, 231–232
Tandem autotransplants, for multiple myeloma, 172–173, 176
T-cell
in AIDS-associated lymphoma, 247–248
in bone-marrow transplant, 347
in Epstein-Barr viral infection, 29, 31
and immunity, 267–272
T-cell lymphoma, 4, 6–7, 8t
as anaplastic large cell lymphoma, 17
Epstein-Barr virus in, 38
ontogeny schematic of, 311f
Thrombocytopenia
in acute lymphoblastic leukemia, 315–316
in myelodysplasia, 285
Thrombopoietin
in leukemic cell proliferation, 197
in myelodysplasia, 285
Thymopentin, for cutaneous T-cell lymphoma, 234–235
Topotecan, 346
Total Therapy trial, 177
Toxin modalities, for MF/SS, 232, 232t
Toxoplasmosis, 258
Translocation. See Chromosome, translocation of
Transplantation therapy, for diffuse aggressive lymphoma, 52–53, 53f
Tretinoin, 140–141
Trlinage response, 342
Tumor burden indicators, in multiple myeloma, 161–164
Tumor necrosis factor (TNF)
in autocrine/paracrine loop, 218
in leukemic cell proliferation, 197–198
Tumor resistance, cellular mechanisms of, 267–268
Tumor suppressor genes, in multiple myeloma, 160

U
University of Arkansas
on multiple myeloma, newly diagnosed patients in, 177
on tandem autotransplants, 172–175
Vaccination, against immunoglobulin receptor, 267–272
Vaccines
for diffuse aggressive lymphoma, 63–64
for non-Hodgkin’s lymphoma, 293–294
Vidarabine, 229
Virions, 27, 28f
Virus capsid antigen (VCA), 31
Vitamin D₃, 342–343

Whole-brain radiation therapy, 322
Working Formulation, in non-Hodgkin’s lymphoma classification, 4–5, 5t
World Health Organization (WHO)
on lymphoproliferative disorders, 18
on non-Hodgkin’s lymphoma classification, 9

Zidovudine (AZT), on NHL, 242